Pieris Pharmaceuticals Inc (PIRS)

[Seel]

I think we have a lot of time here - 18 months of riding peaks and troughs. Science looks great to me - a technology that is unique but highly adaptable to many existing mab's - which is why I think excellent buyout candidate in a few years. And they have a 'sexy' headliner in their pipeline - their HER2 mab/anticalin fusion agent PRS-343. So they have novel tech of anticalin and fusion tech anticalin/mab's. Very very sexy but also almost 2 years out from a maturation point that will attract big attention - Unless one of their existing partners moves in after more preclinical work proves out concepts...Their pipeline has multiple heavyweight contenders. They have evolved monoclonal antibody technology, potentially improving upon that foundation significantly. I'm here for the long ride unless narrative changes and hope to be riding free shares by 2017.